Roivant Sciences Ltd. ROIV NASDAQ

Roivant Sciences Ltd. (ROIV) reported total assets of $5.23B and total liabilities of $251.14M for quarter ending 2025-12-31, resulting in total equity of $4.97B.

The company held $4.53B in cash and short-term investments. Total debt stood at $207.44M, with net debt of $-1.27B. The Debt-to-Equity (D/E) ratio was 0.04 (conservative).

Current ratio is 30.66, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.04, current ratio of 30.66 — balance sheet is strong
• MOAT (68/100) — Total assets $5.23B and equity $4.97B support the company's competitive scale
• VALUE (68/100) — Debt-to-Equity 0.04 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.